Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model

Haemophilia

Volumn 19, Issue 6, 2013, Pages 913-919

  Pastoft, A E ^a,b   Ezban, M ^b   Tranholm, M ^b   Lykkesfeldt, J ^a   Lauritzen, B ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Haemophilia A; Mice; PEGylation; RFVIII; Venous bleeding

Indexed keywords

N8 GP; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLEEDING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; HEMOPHILIA A; INCISION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAPHENOUS VEIN; SINGLE DRUG DOSE;

HAEMOPHILIA A; MICE; PEGYLATION; RFVIII; VENOUS BLEEDING;

ANIMALS; BLEEDING TIME; DISEASE MODELS, ANIMAL; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMORRHAGE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYETHYLENE GLYCOLS; SAPHENOUS VEIN;

EID: 84886641782     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12198     Document Type: Article

References (28)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
2. Valentino LA. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia 2004; 10: 147-57.
3. Valentino LA, Ismael Y, Grygotis M. Novel drugs to treat hemophilia. Expert Opin Emerg Drugs 2010; 15: 597-613.
4. Pipe SW. Hemophilia: new protein therapeutics. Hematology Am Soc Hematol Educ Program 2010; 2010: 203-9.
5. Powell JS, Nugent DJ, Harrison JA et al. Safety and pharmacokinetics of a recombinant factor VIII with PEGylated liposomes in severe hemophilia A. J Thromb Haemost 2008; 6: 277-83.
6. Rottensteiner H, Turecek PL, Pendu R et al. PEGylation or polysialylation reduces FVIII binding to LRP resulting in prolonged half-life in murine models. Blood 2007; 110. Ref Type: Abstract 3150.
7. Lillicrap D. Extending half-life in coagulation factors: where do we stand? Thromb Res 2008; 122(Suppl. 4): S2-8.
8. Thim L, Vandahl B, Karlsson J et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 2010; 16: 349-59.
9. Stennicke HR, Kjalke M, Karpf DM et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013; 14; 121: 2108-16.
10. ®). Haemophilia 2012; 18: 782-8.
11. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
12. Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost 2009; 7: 651-7.
13. Manco-Johnson MJ, Wang C, Konkle BA, Ingram-Rich R, Humes S, Soucie JM. Primary prophylaxis prevents the onset of arthropathy: longitudinal results of 603 boys with severe factor VIII deficiency analyzed through the Centers for Disease Control Universal Data Collection (CDC UDC) Study. Blood 2008; 112: 1164.
14. Lillicrap D. Improvements in factor concentrates. Curr Opin Hematol 2010; 17: 393-7.
15. Tarantino MD, Lail A, Donfield SM et al. Surveillance of infectious complications associated with central venous access devices in children with haemophilia. Haemophilia 2003; 9: 588-92.
16. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009; 6: 1-16.
17. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008; 97: 4167-83.
18. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008; 22: 315-29.
19. Yatuv R, Robinson MA. Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes: a case of FVIII, FVIIa and G-CSF. Expert Opin Drug Deliv 2010; 7: 187-201.
20. Zeuzem S, Heathcote JE, Martin N, Nieforth K, Modi M. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin Investig Drugs 2001; 10: 2201-13.
21. Rytting M. PEG-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther 2010; 10: 833-9.
22. Mei B, Pan C, Jiang H et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
23. Østergaard H, Bjelke JR, Hansen L et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 2333-41.
24. Stennicke HR, Ostergaard H, Bayer RJ et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb Haemost 2008; 100: 920-8.
25. Röstin J, Smeds AL, Akerblom E. B-Domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol. Bioconjug Chem 2000; 11: 387-96.
26. Gritsch H, Siekmann J, Turecek P, Varadi K; Baxter Int Inc., Baxter Healthcare SA, assignees. PEGylated factor VIII (FVIII), useful for treating bleeding disorder associated with functional defects or deficiencies of FVIII. patent US2010168391-A1, 2010.
27. Johansen PB, Bjørn SE, Agersø H et al. Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma. Thromb Haemost 2010; 104: 157-64.
28. Agersø H, Stennicke HR, Pelzer H et al. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. Haemophilia 2012; 18: 941-7.